Why AIM ImmunoTech Stock More Than Doubled Today After a Pancreatic Cancer Trial Surprise
AIM ImmunoTech shares soared over 100% to 92.79 cents on record volume after its pancreatic-cancer trial hit final subject enrollment ahead of schedule. The last patient is set for mid-June treatment, with the main Ampligen efficacy readout due in December. AIM recently raised $2.4 million in a discounted share offering, adding dilution risk. Monday’s rally came as biotech peers fell, highlighting stock-specific momentum.